These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 20088946)
1. Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation. Marchiani S; Tamburrino L; Nesi G; Paglierani M; Gelmini S; Orlando C; Maggi M; Forti G; Baldi E Int J Androl; 2010 Dec; 33(6):784-93. PubMed ID: 20088946 [TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells. Humez S; Monet M; Legrand G; Lepage G; Delcourt P; Prevarskaya N Endocr Relat Cancer; 2006 Mar; 13(1):181-95. PubMed ID: 16601287 [TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells. Li Y; Chen HQ; Chen MF; Liu HZ; Dai YQ; Lv H; Bing Zu X; Qi L Life Sci; 2009 Jun; 84(25-26):882-7. PubMed ID: 19356736 [TBL] [Abstract][Full Text] [Related]
4. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer. Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638 [TBL] [Abstract][Full Text] [Related]
5. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells. Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748 [TBL] [Abstract][Full Text] [Related]
6. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Brass AL; Barnard J; Patai BL; Salvi D; Rukstalis DB Cancer Res; 1995 Jul; 55(14):3197-203. PubMed ID: 7606741 [TBL] [Abstract][Full Text] [Related]
7. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Uysal-Onganer P; Kawano Y; Caro M; Walker MM; Diez S; Darrington RS; Waxman J; Kypta RM Mol Cancer; 2010 Mar; 9():55. PubMed ID: 20219091 [TBL] [Abstract][Full Text] [Related]
9. Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Yano S; Matsuyama H; Hirata H; Inoue R; Matsumoto H; Ohmi C; Miura K; Shirai M; Iizuka N; Naito K Oncol Rep; 2006 Jun; 15(6):1453-60. PubMed ID: 16685379 [TBL] [Abstract][Full Text] [Related]
10. Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells. Seth D; Shaw K; Jazayeri J; Leedman PJ Br J Cancer; 1999 May; 80(5-6):657-69. PubMed ID: 10360641 [TBL] [Abstract][Full Text] [Related]
12. The androgen receptor and prostate cancer invasion. Bonaccorsi L; Muratori M; Marchiani S; Forti G; Baldi E Mol Cell Endocrinol; 2006 Feb; 246(1-2):157-62. PubMed ID: 16376012 [TBL] [Abstract][Full Text] [Related]
13. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line. Valentini A; Biancolella M; Amati F; Gravina P; Miano R; Chillemi G; Farcomeni A; Bueno S; Vespasiani G; Desideri A; Federici G; Novelli G; Bernardini S Drug Metab Dispos; 2007 Jun; 35(6):968-72. PubMed ID: 17371798 [TBL] [Abstract][Full Text] [Related]
14. Secretogranin II is overexpressed in advanced prostate cancer and promotes the neuroendocrine differentiation of prostate cancer cells. Courel M; El Yamani FZ; Alexandre D; El Fatemi H; Delestre C; Montero-Hadjadje M; Tazi F; Amarti A; Magoul R; Chartrel N; Anouar Y Eur J Cancer; 2014 Nov; 50(17):3039-49. PubMed ID: 25307750 [TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features. Alberti C G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206 [TBL] [Abstract][Full Text] [Related]
16. Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines. Bonaccorsi L; Nosi D; Muratori M; Formigli L; Forti G; Baldi E J Mol Endocrinol; 2007 Feb; 38(1-2):51-66. PubMed ID: 17242169 [TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142 [TBL] [Abstract][Full Text] [Related]
18. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R). Ling MT; Wang X; Lee DT; Tam PC; Tsao SW; Wong YC Carcinogenesis; 2004 Apr; 25(4):517-25. PubMed ID: 14688027 [TBL] [Abstract][Full Text] [Related]
19. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359 [TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]